메뉴 바로가기 본문 바로가기

Technologies

R&D Center

BioNote’s R&D Center was accredited as a company research institute by the Korea Industrial Technology Association (KOITA) in 2004, and handles the development of new products and new technologies as well as the improvement of existing products.
The center is composed of the Material Development Team and the Product Development Team.
Within the R&D Center, we possess various cutting-edge research facilities to develop cell lines, culture and purification process, and conduct biological analysis. We also have a separately BL-3 (Biosafety Level 3) research facility to develop products for infectious viral diseases.
The R&D Center is continually striving to develop new products that will fulfill customers requirements whilst conducting ongoing research on the shortcomings of the products to improve the safety, specificity, and sensitivity of our kits.

Material Development Team

  • Antigen Development

    By using cutting edge technology and knowhow, we have enabled the culture, and purification of antigen ingredient used in development of products for on-site diagnosis.
    With gene recombination antigen manufacturing technology using HEK, CHO, E.coli, Baculo, etc. we are dedicated to developing world’s top level products.

  • Antibody Development

    Our experienced researchers perform all work on diagnostic antibody development from the production to purification and screening using a stringent and systematic protocol.
    We utilize recombinant antibody manufacturing technology as well as monoclonal and polyclonal antibody technology which results in a highly sensitive and high yielding antibody.

Product Development Team

We are performing work of developing products of various in vitro diagnosis platforms such as Rapid, ELISA,
and fluorescence immune diagnosis reagents using selected ingredients.
  • Rapid kit

    We are developing a kit that can detect ultrafine concentrations of 1pg per 1mg unit of the target substances by using various nanoparticles (colloidal gold, cellulose particle, and latex particle).
    By independently developing/applying nanoparticle conjugation /application technology, we are developing Rapid kits based on swiftness and convenience.

  • ELISA

    We are developing ELISA kits with top-notch performance by introducing conjugation technology of protein and hapten, and optimal assay format.
    The developed products are supplied to governmental organizations, and actively used in disinfection policies of industrial animals.

  • Plate Coating Technique
    - Stable & High Reproducible coating technology
  • Conjugation Technique
    - Protein-Enzyme conjugation
    - Protein-Small molecule conjugation
    - Protein-Protein conjugation
  • Development Assay Format
    - Sandwich ELISA
    - Indirect ELISA
    - Competitive ELISA
  • Fluorescence Immunoassay
    Diagnostic Reagent

    Using fluorescent material conjugate manufacturing technology, we have developed highly-sensitive fluorescence platforms, which detect antigens and antibodies.

  • Large Scale Biosafety Level 3

    In order to safely produce and perform culture research on high-risk pathogens , which are highly likely to cause harm to the human body, BioNote received permission from the Korea Centers for Disease Control & Prevention (KCDC) in May 2018 for our Large Scale Biosafety Level 3 (BL3) Research Facilities.

    We formed an enclosed area of 106.4m2 where high-risk pathogens could be handled.

    We have installed an Uninterruptible Power Supply (UPS) system and emergency generator to maintain negative pressure at a constant level even in emergency situations in which pathogens could be exposed externally, such as power failures, to prevent pathogens from being leaked out of the laboratory.